Medicaid and the HIV/AIDS epidemic in the United States.

This article explores the impact on Medicaid costs of new AIDS treatments and other technology advances. Available data on total projected Medicaid expenditures and actual expenditures for antiretroviral drugs are presented. The article further addresses Medicaid State agencies' efforts to assure that Medicaid-eligible persons with AIDS receive quality care, and reviews recent studies on utilization of services among persons with HIV disease.